2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Omics Technologies, Computational Biology, Emerging Technologies, Gene Editing, Profiling, Treatment Considerations, Biological Therapies, Checkpoint Inhibitor, Women’s Health, Artificial Intelligence (AI), Machine Learning, Biological Processes, Pathogenesis, Immune Mechanism, Metabolism, Molecular Biology, Diseases, Bleeding and Clotting, Platelet Disorders, Thromboembolism, Thrombotic Disorders, Immunology, Research, Fundamental Science, Translational Research, Study Population, Human, Adult, Animal Model
PAPER

4832 NLRP4 regulates endothelial procoagulant activity in antiphospholipid syndrome (APS)

Bhagwati Joshi, PhD, Paresh P Kulkarni, MBBS, MD, PhD2, Upendra Kumar Singh, PhD3, Keith McCrae, MD4
1 Cleveland Clinic Research, Cleveland, Ohio, United States, Cleveland Clinic Research, Cleveland, Ohio, United States
2 Cleveland Clinic Research, Cleveland, Ohio, United States
3 Cleveland Clinic Research, Cleveland, Ohio, United States
4 Cleveland Clinic Research, Cleveland, Ohio, United States

Background: Antiphospholipid syndrome (APS) is the leading cause of acquired thrombophilia and a major cause of preventable pregnancy morbidity. Endothelial cell (EC) activation is central to APS pathogenesis and is driven by antiphospholipid antibodies (aPL) through β2-glycoprotein I-dependent Toll-like receptor 4 signaling, NF-κB activation, and NLRP3 inflammasome-mediated IL-1β release. While these pathways promote vascular inflammation and thrombosis, endogenous mechanisms limiting EC activation remain poorly defined. NLRP4 is an understudied member of the NOD-like receptor family that negatively regulates innate immune signaling in immune cells, however its role in vascular endothelium is unknown.

Aims: To determine whether endothelial NLRP4 functions as an endogenous suppressor of inflammatory and prothrombotic responses induced by aPL.

Methods: To assess endothelial NLRP4 regulation following exposure to sera from APS patients, human umbilical vein endothelial cells (HUVECs) were incubated with  sera from patients with APS or healthy donors for 6h. NLRP4 expression was evaluated by quantitative PCR, immunoblotting and immunofluorescence. Type I interferon signaling, IL-1β expression, and endothelial activation (cell surface E-selectin) were quantified following transient siRNA-mediated NLRP4 knockdown or plasmid-mediated NLRP4 overexpression. Endothelial procoagulant activity was assessed using a plasma clotting assay under similar conditions.

Results: NLRP4 protein expression was highest in confluent HUVEC monolayers. Exposure to APS sera significantly reduced endothelial NLRP4 mRNA (p≤0.0001) and protein expression (p≤0.0162) compared with healthy donor sera. Loss of NLRP4 was associated with increased type I interferon signaling (p≤0.0001) and IL-1β expression (p≤0.0021), consistent with enhanced inflammatory activation. siRNA-mediated NLRP4 knockdown did not activate quiescent ECs under basal conditions but augmented APS serum-induced endothelial activation, as measured by E-selectin expression (p≤0.0001).. Similar enhancement of endothelial activation following NLRP4 knockdown was observed after stimulation with lipopolysaccharide and TNF-α, suggesting that NLRP4 broadly regulates endothelial innate immune responses beyond APS-specific signaling. Conversely, NLRP4 overexpression significantly attenuated APS serum-induced E-selectin expression compared with control plasmid-transfected ECs (p≤0.0057). Restoration of NLRP4 also decreased the rate of clot formation when recalcified normal human plasma was overlaid on APS serum exposed endothelial cells (NLRP4 transfected, Vmax A405 34.5±8.0; control transfected, Vmax A405 49.8±4.1, p < 0.0376)).

Conclusions: APS sera suppresses endothelial NLRP4 expression, promoting inflammatory signaling and acquisition of a prothrombotic phenotype. Loss of NLRP4 enhances endothelial responsiveness to APS-specific and other inflammatory stimuli, whereas restoration of NLRP4 limits endothelial activation and development of a procoagulant phenotype. These findings identify endothelial NLRP4 as a previously unrecognized endogenous regulator of vascular inflammation and thrombosis and suggest that therapeutic strategies aimed at preserving or restoring NLRP4 function may represent a novel approach for preventing thromboinflammation in APS.

Bhagwati Joshi, PhD: No relevant conflicts of interest to declare.